^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    CD20-targeted CAR-T immunotherapy

    Related drugs:
    1d
    A Study Evaluating the Safety and Efficacy of KITE-363 in Relapsed/Refractory Autoimmune Neurologic Diseases (clinicaltrials.gov)
    P1, N=52, Recruiting, Kite, A Gilead Company | Not yet recruiting --> Recruiting
    Enrollment open • Pan tumor
    |
    LRP4 (LDL Receptor Related Protein 4)
    |
    cyclophosphamide • fludarabine IV • KITE-363
    1d
    A Study to Evaluate the Safety, Tolerability, Cellular Kinetics, and Pharmacodynamics of P-CD19CD20-ALLO1 in Participants With Multiple Sclerosis (clinicaltrials.gov)
    P1, N=60, Active, not recruiting, Genentech, Inc. | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    cyclophosphamide • fludarabine IV • RG6540
    15d
    A Study to Evaluate the Safety, Tolerability, Cellular Kinetics, Pharmacodynamics, and Efficacy of P-CD19CD20-ALLO1 in Participants With Severe, Treatment-refractory Systemic Lupus Erythematosus (SLE) (clinicaltrials.gov)
    P1, N=162, Recruiting, Genentech, Inc. | Initiation date: Feb 2026 --> Jun 2026
    Trial initiation date
    |
    cyclophosphamide • fludarabine IV • RG6540 • rimiducid (AP1903)
    20d
    RN1701 Injection in the Treatment of Relapsed/Refractory B-Cell Lymphomas (clinicaltrials.gov)
    P1/2, N=10, Not yet recruiting, Affiliated Hospital of Nantong University
    New P1/2 trial
    |
    CD20 (Membrane Spanning 4-Domains A1)
    |
    CD20 positive
    21d
    M-2024-424: MB-CART2019.1 in refractory MS (2024-517601-82-00)
    P1/2, N=25, Recruiting, Miltenyi Biomedicine GmbH | Not yet recruiting --> Recruiting
    Enrollment open
    |
    zamtocabtagene autoleucel (MB-CART2019.1)
    1m
    Study Evaluating the Efficacy of KITE-753 Versus Axicabtagene Ciloleucel in Participants With Relapsed or Refractory Large B-Cell Lymphoma After First-Line Therapy (clinicaltrials.gov)
    P3, N=550, Not yet recruiting, Kite, A Gilead Company
    New P3 trial
    |
    cyclophosphamide • Yescarta (axicabtagene ciloleucel) • fludarabine IV
    1m
    PERSIST: Long-Term Follow-Up of AvenCell Sponsored CAR-T Cell Clinical Trials (clinicaltrials.gov)
    P=N/A, N=178, Enrolling by invitation, AvenCell Therapeutics, Inc.
    New trial
    1m
    A Clinical Study Exploring the Safety, Efficacy and Cell Metabolic Kinetics of Universal Car-t Cell Injection in CD19 and / or CD20 Positive Relapsed / Refractory B-cell Acute Lymphoblastic Leukemia in Adolescents, Children and Adults (clinicaltrials.gov)
    P1, N=18, Recruiting, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
    New P1 trial
    |
    CD20 (Membrane Spanning 4-Domains A1)
    |
    CD20 positive
    2ms
    A Study to Evaluate the Safety, Tolerability, Cellular Kinetics, Pharmacodynamics, and Efficacy of P-CD19CD20-ALLO1 in Participants With Severe, Treatment-refractory Systemic Lupus Erythematosus (SLE) (clinicaltrials.gov)
    P1, N=162, Recruiting, Genentech, Inc. | Not yet recruiting --> Recruiting
    Enrollment open
    |
    cyclophosphamide • fludarabine IV • RG6540 • rimiducid (AP1903)
    2ms
    PRO00037171: CAR-20/19-T Cells in Patients With Relapsed Refractory B Cell Malignancies (clinicaltrials.gov)
    P1/2, N=100, Recruiting, Medical College of Wisconsin | Trial completion date: Jun 2028 --> Feb 2029 | Trial primary completion date: Jun 2026 --> Feb 2027
    Trial completion date • Trial primary completion date
    |
    BCL2 (B-cell CLL/lymphoma 2)
    |
    CAR-20/19-T Cells
    2ms
    AVC-203-01: QUADvance: Advancing Allogeneic Quad-CAR01-T Therapy in Hard-to-Treat B-Cell Cancers (2025-521735-36-00)
    P1/2, N=60, Recruiting, Avencell Therapeutics Inc.
    New P1/2 trial
    |
    CD20 (Membrane Spanning 4-Domains A1) • CD19 (CD19 Molecule)
    3ms
    C-CAR168 CAR T Cell Therapy for Refractory Autoimmune Disease (clinicaltrials.gov)
    P1/2, N=24, Not yet recruiting, AbelZeta Inc. | Trial completion date: Dec 2029 --> Jun 2030 | Initiation date: Jan 2026 --> Jul 2026 | Trial primary completion date: Nov 2028 --> May 2029
    Trial completion date • Trial initiation date • Trial primary completion date